Business Context and Reporting Period
This Form 8-K is a current report filed by OncoGenex Pharmaceuticals, Inc. (noted as "ACHIEVE LIFE SCIENCES, INC." in metadata) on March 23, 2012. The filing serves as a Regulation FD disclosure regarding a corporate finance event.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on the execution of an overallotment option by underwriters.
Material Changes
- Overallotment Exercise: On March 23, 2012, the company announced the full exercise of the overallotment option by underwriters.
- Disclosure Method: The information was disseminated via a press release furnished as Exhibit 99.1.
Guidance, Outlook, and Risks
The filing does not contain management commentary, forward-looking guidance, risk factors, or contingencies beyond the announcement of the overallotment exercise. The report explicitly states that the information is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the exact number of shares issued under the full exercise of the overallotment option by reviewing Exhibit 99.1 (the press release).
- Confirm the total gross proceeds generated from the overallotment exercise.
- Check subsequent filings (e.g., 10-Q or 10-K) for the impact of this capital raise on the company's cash position and share count.